
Caris Signs Research Collaboration with mRNA Leader Moderna, Now Has Over 70 Biopharma Partnerships
Caris Life Sciences has signed a new multi-year partnership with Moderna, known for its therapeutic development using mRNA technology. Under the terms of this agreement, Moderna will utilize Caris’s extensive repository of de-identified, multi-modal data. These datasets comprise information derived from whole exome sequencing, whole transcriptome sequencing, protein analyses, and claims data for patients who have undergone comprehensive genomic profiling for cancer. Moderna intends to use the data to support development strategies for its oncology pipeline by optimizing clinical trial design, identifying novel biomarkers, and characterizing resistance mechanisms. The financial terms of the deal were not disclosed.
Caris has profiled over 559,000 cancer patients and through its Precision Oncology Alliance consisting of over 70 cancer treatment centers, it has matched data with medical outcomes on over 390,000 patients. The company currently has over 70 biopharma partnerships.
Praveen Aanur, MD, MPH, MBA, Vice President, Oncology Therapeutic Area Head of Moderna, expressed enthusiasm about this partnership, highlighting how Caris’s industry-leading precision medicine capabilities could provide valuable clinico-genomic data to bolster Moderna’s oncology portfolio.